Timing of Initiating Glycopeptide Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical Outcome
Table 3
Variables associated with 14-day infection-related mortality.
Variable
Yes, No. (%)
No, No. (%)
P-value
No. of patients
38 (11.2)
301 (88.8)
Age in years, median (range)
68 (38–90)
64 (23–88)
0.54
Gender, male
24 (63.2)
190 (63.1)
1.00
Underlying disease/condition
Cardiovascular disease
7 (18.4)
42 (13.9)
0.46
Diabetes mellitus
20 (52.6)
117 (38.9)
0.12
Uremia requiring dialysis
7 (18.4)
59 (19.6)
1.00
Decompensated liver cirrhosis
6 (15.8)
41 (14.6)
0.80
Malignancies
7 (18.4)
57 (18.9)
1.00
Prosthetic device implantation
5 (13.2)
36 (11.9)
0.79
Severity-of-illness markera
Nosocomial acquisition
31 (81.6)
214 (71.1)
0.25
Intensive care unit admission
12 (31.6)
63 (20.9)
0.15
APACHE II score, median (range)
15 (1–38)
11 (2–29)
0.15
APACHE II score >15
10 (26.3)
34 (11.3)
0.02
Source of infectionb
Catheter-related infection
1 (2.6)
39 (12.9)
0.07
Endovascular infection
0
9 (2.9)
0.61
Soft-tissue infection
13 (34.2)
85 (28.2)
0.45
Osteomyelitis
8 (21.1)
59 (19.6)
0.83
Urinary tract infection
0
4 (1.3)
1.00
Pneumonia
15 (39.5)
36 (11.9)
<0.01
Primary bacteremia
6 (15.8)
68 (22.6)
0.41
Timing of initiating glycopeptide therapy
Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO growth
23 (60.5)
168 (55.8)
0.61
BC: blood culture; MRSA: methicillin-resistant S. aureus; No.: number; SLO: Staphylococcus-like organism.
aAt time of blood culture sampling.
bSome patients had more than one infected site.
